drugset
drugset / Trial / NCT05243719

Open-label Extension Study of ADP101

NCT05243719 ↗

Phase 1/2 Terminated 45 enrolled Alladapt Immunotherapeutics, Inc.
NaSingle-groupOpen-labelTreatment

Summary

This is an open-label, safety extension study for participants who participated in the Harmony study (protocol ADP101-MA-01).

Timeline

Start
2022-03-14
Primary completion
2024-02-27
Completion
2024-02-27

Outcome

Outcome not reported

Stopped (Business): “Sponsor decision”

Drugs

EvaluationDrugModalityDoseRoute
Subject ADP101 Unknown — Oral

Indications

food allergy